Safety and Efficacy of Distal Radial Approach (SAFE-BOX)
Launched by YONSEI UNIVERSITY · Mar 8, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The SAFE-BOX trial is a study looking at a new way to perform heart procedures called the distal radial approach. This method involves accessing the heart through the wrist, which may be safer and more comfortable for patients. The trial is currently recruiting participants who are at least 20 years old and need a coronary angiography or other heart interventions. To participate, patients must have a noticeable radial artery in their wrist that the doctors can easily feel.
If you decide to join the trial, you will be part of a group that helps researchers understand how safe and effective this new method is. The study is open to all genders, and it is important to note that some people may not be eligible, such as those with a very small or hard-to-find radial artery, pregnant women, or anyone the researcher feels is not suitable for the study. Your participation could contribute to finding better ways to treat heart conditions!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients over 20 years of age
- • 2. Patients requiring coronary angiography or intervention
- • 3. Patients with palpable distant radial artery
- Exclusion Criteria:
- • 1. Patients with distant radial artery too small or not palpable
- • 2. Pregnant women
- • 3. Patients not appropriate for the researcher to judge
About Yonsei University
Yonsei University, a prestigious institution located in South Korea, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Yonsei University leverages its extensive expertise and innovative approaches in various fields of medicine to conduct rigorous clinical trials aimed at improving patient outcomes and advancing healthcare solutions. The university's robust infrastructure, multidisciplinary collaboration, and adherence to ethical standards ensure the integrity and reliability of its research initiatives, making it a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yongin, Gyeonggi Do, Korea, Republic Of
Patients applied
Trial Officials
Yongcheol Kim, MD, PhD
Study Director
Severance Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials